Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O95999

UPID:
BCL10_HUMAN

ALTERNATIVE NAMES:
B-cell CLL/lymphoma 10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; CED-3/ICH-1 prodomain homologous E10-like regulator; Cellular homolog of vCARMEN; Cellular-E10; Mammalian CARD-containing adapter molecule E10

ALTERNATIVE UPACC:
O95999; Q5VUF1

BACKGROUND:
The protein B-cell lymphoma/leukemia 10, known for its roles in immune system signaling, acts as a linchpin in the activation of NF-kappa-B and MAP kinase pathways. By facilitating the polymerization of BCL10 and formation of the CBM complex, it is essential for the expression of genes encoding pro-inflammatory agents. Its activation is crucial for antifungal immunity and adaptive immune responses, mediated through CARD9 and CARD11.

THERAPEUTIC SIGNIFICANCE:
Given BCL10's involvement in critical immune disorders such as Immunodeficiency 37 and mucosa-associated lymphoid type lymphoma, its study offers a promising avenue for the development of novel therapeutic strategies. Understanding the role of BCL10 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.